Cas tlema n s disease is a rare lytnpltop rolife rative disorder that is easily m isd iagnosed. When it occurs in the head/n eck and thorax, it can pose a diagnostic dilemma becaus e of its lack ofany spe cificpresenting characteristics and distinguishing rad iograp hic f eat ures. An accurate histopath ologic dia gn osis and careful stag ing are crucial to planning treatment. The highly vascular nature of the tum or makes surgical management cha lleng ing, and it warrants preoperative embolization whenever possible.
Introduction
Castleman's disease is a rare lymph oprolifera tive disorder that presents with or without constit utio nal symptoms. Many term s have been used over the years to describe this enti ty, including giant lymph node hyperplasia, angiomatous lymph oid hamartoma, benign giant lymphom a, and fo llic ular lymph oreticul oma , Th e entity was first described in 1956 by Castleman et al as a benign, localized enlarge ment of hyperplastic lymph nodes. ' In 1970 , Flen drig reported that this disorder has two separate histologic features.' Based on these features, Keller et al in 1972 subclassified Castleman's disease into two type s: hyaline-vascular and plasma-cell? In addition, some patien ts have a mi xed variant.
Clini cally, Castlem an 's disease can be either local ized or mu lticentric. The locali zed form is mor e com mon:
• Approx imately 90 % of cases of the localized form are of the hyaline-vascular type. Patients present with a solitary mass, and their disease typically follow s a benign course.'
• Most case s of the multice ntric for m are of the plasm acell type . Patients present with a systemic illness that manifests as dissemi nated lymph nodes, constitutional symptoms (e.g., fatigue, fever, weight loss, and swea ts), autoi mmune abnorma lities, recu rrent infections, and laboratory abnormalities (e.g., anemia, hypoalbuminemia, hypergamm aglob ulinem ia, and an increased erythrocyte sedimentation rate). The multicentric form is aggress ive and often culminates in death secondary to infecti ous co mplications or mal ignancy (e.g. , lympho ma, Kaposi 's sarcoma, or follicu lar dendritic cell sarcoma); malig nanc ies have been reported to arise in as many as 32% of pat ients with mu lticentric Castlem an's disease.' ?
Both the hyaline-va scular and plasma -ce ll types of Castleman' s disease are usua lly acco mpanied by a systemi c inflammatory respo nse. The clinical course may also be complicated by acquired systemic amyloidosi s. Fo llowi ng tumor resection , amyloid deposits and sys temic inflammation regress."
Multicentric Cast leman ' s disease in the absence of human immunodeficiency viru s (HIY) infection is associated with non-Hod gkin 's lymphoma. Hodgkin's disease may occur with the localized form of the plasma-cell type of Castleman's disea se, usuall y in the sa me region.' In HIY-positive patients, multi centric Castleman's disease is assoc iated with hum an herpesvirus type 8 (HHY8), whic h is a Kaposi's-sarcom a-associated herp esvirus. In one study, the incide nce of Kaposi 's-sarcom a-associated, HHY 8-related non-Hod gk in's lymphoma in a coh ort of HIY-positive patients with multicent ric Castleman 's disease was IS-fold higher than the incidence in the general HIY-positive popu lation."
The most common location of Castleman's disease is the thorax; the neck is the second most common site, although on ly about 70 such ca ses have been reported (table 1). 9 Th e disease appears to have a predi lectio n for men , and it usually occ urs in the third through fifth decades of life (the youngest reported pati ent was diag nosed at 6 weeks ENT-Ear, Nose & Throat Joumal s july 2007 
Discussion
Etiology. Numerous etiologies for Castleman 's disease have been proposed in the liter ature . Although its exact cause remains unknown , a mounting body of evidence indicates that a viral infection may make a significant contribution. Several studies have shown that there is an excessive amount ofinterleukin-6 (lL-6) production within Castleman's disease lesions.P:" The natural function of cytokine IL-6 is to increase the proliferation and survival of B cells. It is this Iymphoproliferation of B cells that is the hallmark of Castleman's disease.
Epidemiologic and polymerase chain reaction studies to undergo excision of the mass. She was followed with twice-yearl y CTs, and at 6 years she remained clinicall y asymptomatic, despite the continued slow growth of the tumor. Patient 3. A 25-year-old wom an present ed to an outside clinic with a 6-week history of an enlarging left supraclavicular neck mass. The discovery of the mass had been preceded by numbne ss and tinglin g in her left arm and hand of I week 's duration. The patient had no complaints of airway compromise or dysphagia, and the remainder of her medical history was noncontributory. An open biopsy had resulted in a large amount of blood loss, and the patient required a transfusion . Patholo gy was consistent with Castleman's disease , and the patient was referred to our institution for excision.
On phy sical exa mination, the mass was firm and located on the left side of the neck above the supraclavicular fossa. The mass deviated the trachea to the right. Contrast-enhanced CT of the neck and chest revealed that the 4 x 7-cm mass extended into the mediastinum (figure I). The patient was scheduled for surgery under gener al anesthe sia. Becaus e she had lost so much blood durin g the earlier open biopsy, preoperative embolization was performed (figure 2). Intraoperatively, the mass was found to be lying directly on the left brach ial plexus (figure 3, A), and it was remo ved without complication (figure 3, B). Histopathologic evaluation of the specimen confirmed that it was localized Castleman 's disea se of the hyalinevascular type ( figure 4) . At the 18-month follow-up, the patient remain ed disease-free with no symptoms of brachial plexus compression. of age).5.10-11 The incidence of Castlem an's disea se is low in the pediatric popul ation ; when it does occur, these patients appear to have a more favorable outcome than do adults . 12 Collectively, we were involved in the treatm ent of 3 patients with Castleman's disease. Patients I and 2 were treated at Wilford Hall Medic al Cente r in San Antonio , Texas , by two of the authors (J.L.N. and J.B. ), and patient 3 was treated at The Johns Hopkins Hospital in Baltimore by the third author (M.C.). All 3 patients had the localized form and the hyaline-vascular type of Castlem an' s disease as determined by surgical lymph node biopsy. Follo w-ups were conducted by clinic visits and telephone interviews. In this article, we describe these 3 cases, and we review the entire course of Castlem an's disease, including its clinic al feature s at presentation, its histopathologic characteristics, and the diagnostic and treatment challenges it pose s.
Case reports
Patient 1. A 58-ye ar-old woman presented with a 5-year history of a persistent, enlarging left lateral neck mass. Because she had previou sly undergone multiple excision s of benign neuromas in her neck, we suspected that this mass represented another recurrence. The patient also complained of right-sided neck numbness and tingling .The remainder of her medic al history was unrem arkable.
On magnetic resonance imaging (MRI), the mass mea- have show n that Castleman's disease is strongly asso ciated with HHV8.13·16-1 8 Th e genome of this viru s harbors an analog of the IL-6 gene. It has been proven that the introductio n of HHV8 into mice via a retroviral vector causes polyclonal hypergammaglobulinemia with plasma-cell hyperpl asia,and the resulting condition mimics multicentric Castleman 's disease. 15 .19Furthermore, treatment of multice ntric Castlem an 's disease with monoclonal antibodies against IL-6 con fers therap eutic benefits."
Diagnosis. At present ation , Castlem an 's disease can pose several diagnostic dilemmas. Most often it manife sts as an asy mptomatic, unifocal, soft-ti ssue mass without any trademark sig ns or symptoms. Becau se of its nonspecific characteristics and the fact that it ca n mimic other neoplasm s, it is often misdiagnosed."
Fine-needle aspira tion cytology is typic ally nondi agno stic. In fact, the presence of lymphoid tissue in the aspirate may actually lead to a misdiagno sis of lymphoma. Keep in mind, however, that both the multi centric and unifoc al for ms have been asso ciated with Iymph om a.t?
With contrast, CT and MRI demonstrate a hom ogeneou sly enh ancing mass. Th e enh ancement is somewhat less pron oun ced in the plasma-cell type becau se it is less vasc ular. CT may exclude fatty or cystic masses, and the administration of contrast may prompt the surge on to erroneously rule out the possibility of thymoma and lymphom a because these tum ors generally do not enhance."
Gallium scanning is ofl ittle help in diagnosing multicentric plasma-cell Castlem an 's disease, although it is useful for detectin g malignant lyrnphoma.P As a consequence of all the se uncertainties, the differential diagnosis of Castleman ' s disease is extensive (table 2) . Th e most reliable way to es tablish a definitive diagnosis is by surgical resect ion and histop athol ogic confi rmation . In the hyaline-vascula r type of Castleman's disease, the classic histopathologic findin gs are the presence of "burne d-out" germinal centers and an "o nion-skin" pattern of concentric exp ansion of the mantle zon es. A single vessel is often Most patients experience a po lyclonal lymphoproliferative process. When monoclonality develops, transformation to a maligna nt lymphoma must be suspected. Imm unohistochemical and gene -rearrangement studies help iden tify those clonal cell populations. 10 Treatment. Careful staging following a histopathologic diagnosis is critical to proper treatment, and almos t all cases will require therapy.
Most patients with unicentric Castleman's disease can be treated with co mplete surgical ablation.' Rare recurrences of localized cases have been assoc iated with inco mplete surgica l removal.' The masses in Castleman's disea se are quite vasc ular, so embolizatio n before extirpation may reduce intraoperative bleeding and facilitate the excision. 22 ,24 However, most cases are diagnosed only after surgical excis ion, so preoperative embo lizatio n is usually moot. For patients with localized disease that is not amenable to complete resection, radia tion therapy may be successfu l. 10 Multicentric Castleman 's disease with systemic manifesta tions is more difficult to treat. A range of treatments is directed at palliation of symptoms. The results of radiotherapy have been inconsistent." Corticosteroids may be used in patients with disseminated disease . Comb ination chemotherapy is used in patients who do not respon d to corticosteroi ds. Castlema n's disease is often treated with the same chemotherapeu tic regi mens that are used to treat lymphomas, but morb idity and mortality secon dary Volume 86, Number 7 to infections are high for patients who receive combined cyclophos phamide, vincristi ne, and predniso ne; in such cases, referral to a medical oncologist is recommended. Erythropoieti n can successfully treat assoc iated severe anemia. Murine anti-IL-6 monoclonal antibody allevia tes symptoms and drama tically improves abnormal laboratory values, although these abnormalities return upon cessation of therapy. The only comp lete remiss ions have been achieved with multiple-agent chemotherapy with or without steroids, with response rates as high as 93%.4,5.18 A trial of 60 to 100 mg of prednisone for weeks to months may also achieve a remission.
Biopsy may be required to assess whether multicen tric Cast leman's disease is progre ssing despite treatme nt. Combined cyclophosphamide, vincristine, and predniso ne or even a bone marrow transplant may be considered for patients with unresponsive, progressive disease.'? Followup is particularly importa nt for patie nts with multicen tric disease because of the potential for the deve lopmen t of malignancy or a fatal infection.
In conclusion, the astute clinician sho uld be aware of Castleman's disease and consider it in the differential diagnosis of any solid tumor that exhi bits nonspecific presen ting charac terist ics.
An alternative to our appro ach is endo scopic removal. Howe ver, removing the lesion with forceps may lead to a recurren ce if the tissue is not removed adequately. Moreover, endo scopic removal also carries a risk of uncontrollable bleeding .I I Endoscopic removal can best be achieved with a laser. Soylu et al successfully used a CO 2 laser to vaporize intratracheal thyroid tissue. IS Even when the endoscopic method is chosen, a preoper ative tracheotomy must be performed to prevent major complications, such as bleedin g and edema-induced airway obstruction.
